Search

Your search keyword '"Holzmayer, Samuel"' showing total 15 results
Start Over Author "Holzmayer, Samuel"
15 results on '"Holzmayer, Samuel"'

1. First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

Author

Rudalska, Ramona, Harbig, Jule, Forster, Michael, Woelffing, Pascal, Esposito, Aylin, Kudolo, Mark, Botezatu, Adelina, Haller, Vanessa, Janssen, Nicole, Holzmayer, Samuel, Nahidino, Philipp, Trompak, Omelyan, Pantsar, Tatu, Kronenberger, Thales, Yurttas, Can, Rist, Elke, Weber, Alexander N. R., Dahlke, Marc H., Ott, German, Koenigsrainer, Alfred, Rothbauer, Ulrich, Maerklin, Melanie, Muerdter, Thomas, Schwab, Matthias, Singer, Stephan, Zender, Lars, Laufer, Stefan, and Dauch, Daniel

Published
2025
Full Text
View/download PDF

3. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Author

Heitmann, Jonas S., Tandler, Claudia, Marconato, Maddalena, Nelde, Annika, Habibzada, Timorshah, Rittig, Susanne M., Tegeler, Christian M., Maringer, Yacine, Jaeger, Simon U., Denk, Monika, Richter, Marion, Oezbek, Melek T., Wiesmüller, Karl-Heinz, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Schroeder, Sarah M., Hoenisch Gravel, Naomi, Scheid, Jonas, Märklin, Melanie, Henrich, Annika, Klimovich, Boris, Clar, Kim L., Lutz, Martina, Holzmayer, Samuel, Hörber, Sebastian, Peter, Andreas, Meisner, Christoph, Fischer, Imma, Löffler, Markus W., Peuker, Caroline Anna, Habringer, Stefan, Goetze, Thorsten O., Jäger, Elke, Rammensee, Hans-Georg, Salih, Helmut R., and Walz, Juliane S.

Published
2023
Full Text
View/download PDF

4. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Author

Ho, Jenny N.H.G., Schmidt, Dominik, Lowinus, Theresa, Ryoo, Jeongmin, Dopfer, Elaine-Pashupati, Gonzalo Núñez, Nicolás, Costa-Pereira, Sara, Toffalori, Cristina, Punta, Marco, Fetsch, Viktor, Wertheimer, Tobias, Rittmann, Marie-Claire, Braun, Lukas M., Follo, Marie, Briere, Christelle, Vinnakota, Janaki Manoja, Langenbach, Marlene, Koppers, Felicitas, Shoumariyeh, Khalid, Engel, Helena, Rückert, Tamina, Märklin, Melanie, Holzmayer, Samuel, Illert, Anna L., Magon, Federica, Andrieux, Geoffroy, Duquesne, Sandra, Pfeifer, Dietmar, Staniek, Julian, Rizzi, Marta, Miething, Cornelius, Köhler, Natalie, Duyster, Justus, Menssen, Hans D., Boerries, Melanie, Buescher, Joerg M., Cabezas-Wallscheid, Nina, Blazar, Bruce R., Apostolova, Petya, Vago, Luca, Pearce, Erika L., Becher, Burkhard, and Zeiser, Robert

Published
2022
Full Text
View/download PDF

8. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.

Author

Holzmayer, Samuel J., Liebel, Kai, Hagelstein, Ilona, Salih, Helmut R., and Märklin, Melanie

Subjects
BISPECIFIC antibodies, SARCOMA, T cells, T cell differentiation, LYSIS, SYNOVIOMA
Abstract

Sarcomas are rare and heterogeneous malignancies that are difficult to treat. Approximately 50% of patients diagnosed with sarcoma develop metastatic disease with so far very limited treatment options. The transmembrane protein B7-H3 reportedly is expressed in various malignancies, including different sarcoma subtypes. In several cancer entities B7-H3 expression is associated with poor prognosis. In turn, B7-H3 is considered a promising target for immunotherapeutic approaches. We here report on the preclinical characterization of a B7-H3xCD3 bispecific antibody in an IgG-based format, termed CC-3, for treatment of different sarcoma subtypes. We found B7-H3 to be expressed on all sarcoma cells tested and expression on sarcoma patients correlated with decreased progression-free and overall survival. CC-3 was found to elicit robust T cell responses against multiple sarcoma subtypes, resulting in significant activation, release of cytokines and effector molecules. In addition, CC-3 promoted T cell proliferation and differentiation, resulting in the generation of memory T cell subsets. Finally, CC-3 induced potent target cell lysis in a target cell restricted manner. Based on these results, a clinical trial evaluating CC-3 in soft tissue sarcoma is currently in preparation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

Author

Kaidun, Polina, primary, Holzmayer, Samuel J., additional, Greiner, Sarah M., additional, Seller, Anna, additional, Tegeler, Christian M., additional, Hagelstein, Ilona, additional, Mauermann, Jonas, additional, Engler, Tobias, additional, Koch, André, additional, Hartkopf, Andreas D., additional, Salih, Helmut R., additional, and Märklin, Melanie, additional

Published
2023
Full Text
View/download PDF

10. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Author

Ho, Jenny N H G, Schmidt, Dominik, Lowinus, Theresa, Ryoo, Jeongmin, Dopfer, Elaine-Pashupati, Gonzalo Núñez, Nicolás, Costa-Pereira, Sara, Toffalori, Cristina, Punta, Marco, Fetsch, Viktor, Wertheimer, Tobias, Rittmann, Marie-Claire, Braun, Lukas M, Follo, Marie, Briere, Christelle, Vinnakota, Janaki Manoja, Langenbach, Marlene, Koppers, Felicitas, Shoumariyeh, Khalid, Engel, Helena, Rückert, Tamina, Märklin, Melanie, Holzmayer, Samuel, Illert, Anna L, Magon, Federica, Andrieux, Geoffroy, Duquesne, Sandra, Pfeifer, Dietmar, Staniek, Julian, Rizzi, Marta, et al, and University of Zurich

Subjects
1307 Cell Biology, 2403 Immunology, 1303 Biochemistry, 2720 Hematology, 570 Life sciences, biology, 610 Medicine & health, 10263 Institute of Experimental Immunology
Published
2022

13. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Author

Walz, Juliane, primary, Heitmann, Jonas, additional, Tandler, Claudia, additional, Marconato, Maddalena, additional, Habibzade, Timursah, additional, Rittig, Susanne, additional, Tegeler, Christian, additional, Nelde, Annika, additional, Maringer, Yacine, additional, Jäger, Simon, additional, Denk, Monika, additional, Richter, Marion, additional, Oezbek, Melek, additional, Wiesmüller, Karl-Heinz, additional, Bauer, Jens, additional, Rieth, Jonas, additional, Wacker, Marcel, additional, Schroeder, Sarah, additional, Gravel, Naomi Hoenisch, additional, Märklin, Melanie, additional, Henrich, Annika, additional, Klimovich, Boris, additional, Clar, Kim, additional, Lutz, Martina, additional, Holzmayer, Samuel, additional, Hoerber, Sebastian, additional, Peter, Andreas, additional, Meisner, Christoph, additional, Fischer, Imma, additional, Löffler, Markus, additional, Peuker, Caroline, additional, Habringer, Stefan, additional, Goetze, Thorsten, additional, Jäger, Elke, additional, Rammensee, Hans-Georg, additional, and Salih, Helmut, additional

Published
2022
Full Text
View/download PDF

14. Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)

Author

Kaban, Kübra, Greiner, Sarah M., Holzmayer, Samuel, Tandler, Claudia, Meyer, Sophie, Hinterleitner, Clemens, Salih, Helmut R., Märklin, Melanie, and Heitmann, Jonas S.

Subjects
Medicine (General), R5-920, GITR/GITRL, 4-1BB/4-1BBL, survival, Article, CLL
Abstract

Recent success of novel therapies has improved treatment of chronic lymphocytic leukemia (CLL) patients, but most of them still require several treatment regimes. To improve treatment choice, prognostic markers suitable for prediction of disease outcome are required. Several molecular/genetic markers have been established, but accessibility for the entirety of all patients is limited. We here evaluated the relevance of GITR/4-1BB as well as their ligands for the prognosis of CLL patients. Surface expression of GITR/GITRL and 4-1BB/4-1BBL was correlated with established prognostic markers. Next, we separated our patient population according to GITR/GITRL and 4-1BB/4-1BBL expression in groups with high/low expression levels and performed Kaplan-Meier analyses. Interestingly, no correlation was observed with the defined prognostic markers. Whereas no significant difference between high and low expression of GITR, GITRL and 4-1BBL was observed, high 4-1BB levels on leukemic cells were associated with significantly shorter survival. Thereby we identify 4-1BB as prognostic marker for CLL.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results